

Contains Nonbinding Recommendations

Draft – Not for Implementation

Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This draft guidance document is being distributed for comment purposes only.

Document issued on: March 29, 2023

You should submit comments and suggestions regarding this draft document within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852-1740. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this document, contact OHT6: Office of Orthopedic Devices/DHT6C: Division of Restorative, Repair and Trauma Devices at (301) 796-5650.



**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health**

Contains Nonbinding Recommendations

Draft – Not for Implementation

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an email request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please include the document number GUI00019023 and complete title of the guidance in the request.

DRAFT

Contains Nonbinding Recommendations

Draft – Not for Implementation

Table of Contents

I.	INTRODUCTION	1
II.	BACKGROUND	2
III.	SCOPE	2
IV.	PREMARKET SUBMISSION RECOMMENDATIONS	4
	A. Indications for Use.....	4
	B. Device Description.....	5
	C. Predicate Comparison	10
	D. Labeling	13
	E. Sterility.....	14
	F. Reprocessing (including single-use devices provided non-sterile and intended for sterile processing)	14
	G. Pyrogenicity	16
	H. Shelf Life and Packaging	16
	I. Biocompatibility	17
	J. Magnetic Resonance (MR) Compatibility for Passive Implants	19
	K. Non-Clinical Testing.....	19
	1. Plate Mechanical Performance	21
	2. Screw Mechanical Performance	22
	3. Computational Modeling and Engineering Analysis.....	23
	L. Non-Clinical Animal and/or Clinical Performance Testing	25
V.	MODIFICATIONS (DEVICES SUBJECT TO 510(K)).....	26
	APPENDIX A EXAMPLE TABLE OF PLATE TEST METHODS AND DATA SUMMARY	29
	APPENDIX B EXAMPLE TABLE OF SCREW TEST METHODS AND DATA SUMMARY	31

Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

This draft guidance document provides recommendations for premarket notification (510(k)) submissions for non-resorbable bone plate, screw, and washer devices. These devices are indicated for orthopedic bone fixation and exclude indications for spinal, mandibular, maxillofacial, cranial, and orbital fracture fixation.

For the current edition of the FDA-recognized consensus standard(s) referenced in this document, see the [FDA Recognized Consensus Standards Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm).¹ For more information regarding use of consensus standards in regulatory submissions, please refer to the FDA guidance titled “[Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices).”²

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

¹ Available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

² Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

32 **II. Background**

33 Non-spinal, non-resorbable bone plates, screws and washers are implants intended for bone
34 fixation. These are class II medical devices for which the safety and effectiveness are well-
35 established. This guidance is intended to facilitate consistency in information provided in
36 submissions by addressing common deficiencies related to device description and performance
37 testing and by identifying applicable cross-cutting guidances and consensus standards. Certain
38 orthopedic non-spinal metallic bone screws and washers under product codes HTN and HWC
39 and non-spinal bone plates under product code HRS (see Section III. Scope below for more
40 information) may also be appropriate for submission of a 510(k) through the [Safety and
41 Performance Based Pathway](#).³ For more information, refer to FDA’s guidance entitled
42 “[Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety
43 and Performance Based Pathway](#)”⁴ and “[Orthopedic Fracture Fixation Plates - Performance
44 Criteria for Safety and Performance Based Pathway](#).”⁵

45
46 This document supplements other FDA documents regarding the specific content requirements
47 of a premarket notification (510(k)) submission. You should also refer to 21 CFR 807.87, 21
48 CFR 814.20 and FDA’s guidance, “[Format for Traditional and Abbreviated 510\(k\)s](#).”⁶

50 **III. Scope**

51 The scope of this document is limited to class II, orthopedic, non-resorbable, non-spinal bone
52 plate and screw systems, stand-alone bone screws, and associated washers. These devices are
53 regulated under 21 CFR 888.3030 and 21 CFR 888.3040 with the product codes listed in the
54 table below:

56 **Table 1 – Relevant Product Codes**

57

Product Code	Regulation Number	Name
HRS	21 CFR 888.3030	Plate, Fixation, Bone
HWC	21 CFR 888.3040	Screw, Fixation, Bone
HTN	21 CFR 888.3030	Washer, Bolt Nut
NDG	21 CFR 888.3030	Washer, Bolt, Nut, Non-Spinal, Metallic

58
59 Devices that fall within the scope of this guidance document are comprised of non-resorbable
60 metallic or polymeric components such as, but not limited to, those manufactured from:

³ See <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway>.

⁴ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-safety-and-performance>.

⁵ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-fracture-fixation-plates-performance-criteria-safety-and-performance-based-pathway>

⁶ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/format-traditional-and-abbreviated-510ks-guidance-industry-and-fda-staff>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 61 • titanium alloy (e.g., per ASTM F136 *Standard Specification for Wrought Titanium-*
62 *6Aluminum-4Vanadium ELI (Extra Low Interstitial) Alloy for Surgical Implant*
63 *Applications (UNS R56401)* or ASTM F1295 *Standard Specification for Wrought*
64 *Titanium-6Aluminum-7Niobium Alloy for Surgical Implant Applications (UNS*
65 *R56700)),*
- 66 • commercially pure titanium (e.g., per ASTM F67 *Standard Specification for Unalloyed*
67 *Titanium, for Surgical Implant Applications (UNS R50250, UNS R50400, UNS R50550,*
68 *UNS R50700)),*
- 69 • stainless steel (e.g., per ASTM F138 *Standard Specification for Wrought 18Chromium-*
70 *14Nickel-2.5Molybdenum Stainless Steel Bar and Wire for Surgical Implants (UNS*
71 *S31673)),*
- 72 • cobalt-chrome alloy (e.g., per ASTM F1537 *Standard Specification for Wrought*
73 *Cobalt-28Chromium-6Molybdenum Alloys for Surgical Implants (UNS R31537, UNS*
74 *R31538, and UNS R31539)),*
- 75 • polyetheretherketone (PEEK) (e.g., per ASTM F2026 *Standard Specification for*
76 *Polyetheretherketone (PEEK) Polymers for Surgical Implant Applications),* or
- 77 • chopped carbon fiber reinforced (CFR) PEEK (e.g., per ASTM F3333 *Standard*
78 *Specification for Chopped Carbon Fiber Reinforced (CFR) Polyetheretherketone*
79 *(PEEK) Polymers for Surgical Implant Applications).*

80
81 This guidance document does not specifically address non-spinal bone plate, screw, and washer
82 devices with the following characteristics:

- 83 • nitinol devices,
- 84 • coated devices,
- 85 • devices with surface modifications,
- 86 • devices incorporating antimicrobial agents,
- 87 • devices with complex geometries,
- 88 • devices with differing modularities,
- 89 • devices with unique geometric features,
- 90 • devices that utilize unconventional surgical techniques (e.g., those that differ from open
91 reduction and internal fixation),
- 92 • resorbable devices,
- 93 • additively manufactured devices, or
- 94 • devices possessing other unique technological characteristics.

95
96 If any of the above characteristics pertain to your device, we recommend submitting a Pre-
97 Submission to obtain Agency feedback. For further information regarding the Q-Submission
98 Program, refer to [“Requests for Feedback and Meetings for Medical Device Submissions: The
99 Q-Submission Program.”](#)⁷

100
101 In addition, this guidance document does not address the following device types:

⁷ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 102 • Bone plates and screws that are intended for mandibular, maxillofacial, cranial, and
103 orbital fracture fixation;
- 104 • Bone plates and screws that are intended for use in the spine and suture anchors; and
- 105 • Fixation components that are part of a bone anchor tightrope (bone-to-bone or soft
106 tissue-to-bone), such as those used for reinforcing ankle syndesmosis or correcting
107 union angular deformities.
108

109 **IV. Premarket Submission Recommendations**

110 **A. Indications for Use**

111 For each subject device, the intended use(s)/indications(s) should be stated, and a comparison of
112 the intended use/indications for use to one or more legally marketed predicate device(s) should
113 be included in your submission. Please note that differences in indications for use (e.g., disease
114 condition, patient population) may prompt a request for additional information to support the
115 new indication.⁸
116

117 Examples of uses that have been cleared for these types of 510(k)s include:

- 118 • long bone fracture fixation⁹
- 119 • small bone fracture fixation¹⁰
- 120 • small bone fragment fixation
- 121 • fracture fixation of specific anatomical locations (e.g., femur, tibia, fibula, clavicle,
122 humerus, olecranon)
- 123 • arthrodesis of a joint or osteotomy of the small bones
- 124 • as components of specific cerclage systems
125

126 We recommend that the indication for use statements for these devices, avoid vague language
127 (e.g., “bone fixation,” “small bones”) to help reduce ambiguity and clarify appropriate device
128 use. Additionally, 510(k) submissions involving any spinal or non-orthopedic uses should be
129 submitted in a separate 510(k) submission to the appropriate review group or Office of Health
130 Technology.
131

132 If seeking an indication for use in osteopenic bone, comparison should be made to one or more
133 legally marketed predicate device(s) intended for use in the same anatomical location with

⁸ Within the 510(k) paradigm, any change in indications for use that raises different questions of safety and effectiveness and therefore precludes a meaningful comparison with the predicate device constitutes a new intended use and would be deemed “not substantially equivalent” to the predicate device. See also FDA’s guidance “[The 510\(k\) Program: Evaluating Substantial Equivalence in Premarket Notifications \[510\(k\)\]](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k),” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k>.

⁹ The term “long bone” refers to fracture fixation of the femur, tibia, fibula, humerus, ulna, and radius.

¹⁰ The term “small bone” refers to fracture fixation of the wrist, hand, and foot.

Contains Nonbinding Recommendations

Draft – Not for Implementation

134 similar indications. If seeking indications for osteoporotic bones or “poor bone quality”¹¹ (e.g.,
135 lower bone mineral density (BMD) attributable to Type I diabetes mellitus), additional
136 information may be requested to demonstrate performance of the implant in the simulated use
137 and bone condition to support the indications for use.

138
139 For bone plates or screws with pediatric indications, you should identify the pediatric
140 subpopulations that the devices are intended to treat. Refer to the guidance document entitled
141 “[Premarket Assessment of Pediatric Medical Devices](#)”¹² for more information.

142 B. Device Description

143 We recommend you identify your device by the applicable regulation number and product code
144 indicated in Section III above and include the information described below.

145
146 For bone plates and screws, we recommend that you provide images of the device and the
147 following system level overview information in tabular format, for example, as shown in Table
148 2:

149
150 **Table 2 – General System Descriptive Information**
151

System Description	Subject Device (Examples)
Intended use	<i>Fracture fixation; joint arthrodesis</i>
Product code	<i>HRS</i>
Target population	<i>Adults only; pediatrics; adults and pediatrics</i>
Anatomical site(s) of use	<i>Long bones; proximal humerus; Tarsometatarsophalangeal joint</i>
Provided sterile/non-sterile	<i>Provided non-sterile; Provided sterile</i>
Sterilization method	<i>Steam; gamma irradiation</i>
Shelf life	<i>N/A; 2 years</i>
Packaging (if provided sterile)	<i>N/A</i>
System components that can be reprocessed and, if so, are cleaning	<i>All instruments, cleaning instructions included in the Instructions for Use</i>

¹¹ Bone quality refers to those structural and material properties of bone that determine its biomechanical behavior in ways that are not accounted for by bone quantity or mass. For orthopedic devices, FDA defines the term “poor bone quality” as impaired bone strength (biomechanical performance) sufficient to increase fracture risk or hardware failure that is not accounted for by measured bone density.

¹² <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premarket-assessment-pediatric-medical-devices>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

instructions included and location within submission	
Summary of how the device achieves its intended function	<i>Bone plates are used in conjunction with compatible bone screws to create a stabilized construct that promotes fracture healing. The system contains locking and nonlocking screws. Screw holes and screw head design allow variable angle placement within a 15 degree cone.</i>

152
153 The submission should include a table with the name of each component in the system with its
154 associated part number. Descriptive information for each component should include critical
155 dimensions for the entire range of available sizes in tabular format. Examples of recommended
156 information to include and example format for critical dimensions for bone plates, bone screws,
157 and washers/bolt nuts are provided in Tables 3, 4, and 5 below. For submissions that include
158 multiple designs or device types, a separate table for each design or device type should be
159 included in the device description section with the information as outlined below. For any FDA-
160 recognized consensus standards referenced in these tables, we recommend you specifically state
161 the edition of the standard that was used.

162
163 For each plate design you should include the information found in Table 3.

Table 3 – Plate Descriptive Information

Plate Description	Subject Device (Examples)
Representative image or photograph of component	
Anatomical site of use	<i>Long bone diaphysis; long bone epiphysis;</i>
Materials	<i>Ti-6Al-4V titanium alloy; Cobalt-Chrome</i>
Any standards to which the materials conform	<i>ASTM F136; ASTM F1537</i>
General plate shape	<i>T-plate; straight plate</i>
Number of holes	<i>X number of holes</i>
Hole dimensions	<i>Y mm hole diameter</i>
Locking mechanism, if applicable	<i>Non-locking</i>

Contains Nonbinding Recommendations

Draft – Not for Implementation

Plate Description	Subject Device (Examples)
Screw angle placement ability relative to plate	<i>Orthogonal placement; fixed angle placement; variable angle placement in a 15 degree polyaxial cone for locking screws only</i>
Plate width range (minimum and maximum in the structurally critical region)	<i>A – B mm</i>
Plate length range	<i>C – D mm</i>
Plate thickness range (minimum and maximum in the structurally critical region)	<i>E – F mm</i>
Previously cleared compatible screws	<i>2.7mm screws lengths 10mm – 30mm; 510(k) number(s)</i>
New proposed compatible screw sizes	<i>3.0mm diameter cortical screws and 4.5mm cancellous screws in lengths 8mm – 40mm.</i>
Compatible screw features	<i>Locking, 10 degree variable angle locking screws</i>

167
168
169
170
171

For each screw design you should include the information found in Table 4.

Table 4 – Stand-Alone Screw Descriptive Information

Screw Description	Subject Device (Examples)
Representative image or photograph of component	
Materials	<i>316L Stainless Steel; CP Ti Grade 4</i>
Any standards to which the materials conform	<i>ASTM F138; ASTM F67</i>
Type of screw	<i>Cortical; Snap-off</i>
If cannulated, cannula diameter	<i>A mm diameter</i>
Screw length range	<i>B – C mm</i>
Length of threaded region range	<i>D – E mm</i>
Minor screw diameter range	<i>F – G mm</i>
Major screw diameter range	<i>H – I mm</i>
Thread pitch range	<i>J – K mm</i>

Contains Nonbinding Recommendations

Draft – Not for Implementation

172
173
174
175
176

For each washer/bolt nut design you should include the information found in Table 5.

Table 5 – Washer Descriptive Information

Washer/Bolt Nut Description	Subject Device (Examples)
Representative image or photograph of component	
Materials	<i>316L Stainless Steel</i>
Any standards to which the materials conform	<i>ASTM F138</i>
Inner diameter range	<i>A – B mm</i>
Outer diameter range	<i>C – D mm</i>
Thickness range	<i>E – F mm</i>
Previously cleared compatible screws	<i>510(k) number(s)</i>
New proposed compatible screws	<i>Subject screw diameters in mm</i>

177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201

You should submit engineering drawings for each size and part number that include critical dimensions and tolerances. Alternatively, you should supply representative drawings with a table of each part number that includes critical dimensions, as follows, for each size:

- Plates: plate angulation (if applicable), minimum and maximum length, minimum and maximum width in the structurally critical region, minimum and maximum thickness in structurally critical region, screw hole diameter, and distance between screw holes.
- Screws: minimum and maximum length, threaded diameter, core diameter, axial thread length, thread pitch, screw head diameter, height, and thread feature if applicable.

For devices incorporating embedded fibers, such as carbon fiber reinforced PEEK (CFR PEEK), the following material parameters should be included in the device description: percent fiber used, length of fibers (average and distribution), fiber direction, and sizing agent used (for interfacial adhesion between fiber and polymer). These parameters may impact the conditions under which delamination between fiber and matrix occurs, which could impact device performance. This is further discussed in Section IV.J below.

If the device is provided with surgical instrumentation, the instruments should also be identified in the submission, along with the associated classification regulation(s). For example, many instruments that are for general use and can be used in any generic orthopedic bone plate or screw implantation procedure, are regulated under 21 CFR 878.4800 Manual surgical instrument for general use or 21 CFR 888.4540 Orthopedic manual surgical instrument. These instruments are considered class I and are exempt from 510(k) review. Descriptive information, as shown in

Contains Nonbinding Recommendations

Draft – Not for Implementation

202 Table 6, for class II, device-specific instruments¹³ should be included in the device description
203 section of your submission.

204 **Table 6 – Device-Specific Instrument Descriptive Information**
205
206

Instrumentation Description	Subject Instrument (Examples)
Name of the instrument and part number	<i>Snap-off screwdriver; Volar plate head drill guide block</i>
510(k) number if instrument has been previously cleared	<i>New instrument</i>
Representative engineering drawing(s), schematic, illustration, photograph and/or figure	<i>See section X, page Y for engineering drawing</i>
Purpose and brief description of the instrument	<i>Intended to interact specifically with the handle of the screw to allow removal upon clockwise twisting of the driver after the screw is fully seated; Intended to guide screw placement directly into unique screw hole pattern on the head of the plate</i>
Statement clarifying if the instrument is single-use or reusable	<i>Reusable; single-use</i>
Provided sterile/non-sterile	<i>Non-sterile; sterile</i>
Sterilization method	<i>Steam; Ethylene oxide</i>
Materials	<i>PEEK, Stainless steel</i>
Any standards or material specifications to which the materials conform	<i>Master file number; ASTM F899</i>
Duration of contact with the patient	<i>Transient contacting during screw insertion; limited contact for the entire duration of surgery</i>

¹³ A device-specific orthopedic instrument is considered to be an accessory designed specifically for appropriate implantation or placement of the parent device, based upon unique dimensions, geometry, and/or deployment. See 84 FR 14865.

Contains Nonbinding Recommendations

Draft – Not for Implementation

Instrumentation Description	Subject Instrument (Examples)
Color additives, if included in patient contacting components	<i>Blue color additive X in the handle; red color additive Z in the implant</i>

207 C. Predicate Comparison

208 For devices reviewed under the 510(k) process, manufacturers should compare their new device
209 to a similar legally marketed predicate device to support its substantial equivalence ((section
210 513(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act); 21 CFR 807.87(f)))) unless
211 utilizing the optional approach identified in the FDA guidance “[Safety and Performance Based](#)
212 [Pathway](#).”¹⁴ (See “[Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance](#)
213 [Criteria for Safety and Performance Based Pathway](#)”¹⁵ and “[Orthopedic Fracture Fixation Plates](#)
214 [- Performance Criteria for Safety and Performance Based Pathway](#)”¹⁶). This comparison should
215 provide information to show how your device is similar to and different from the predicate. Side
216 by side comparisons, whenever possible, are desirable. See Tables 7, 8, 9, and 10 below for
217 examples of how this information can be organized. These tables are not intended to represent an
218 exhaustive list of comparative parameters; ensure you provide all relevant device descriptive
219 characteristics as outlined in Section IV.B, above. The predicate device comparison section of
220 your submission should also include a discussion of why any differences in technological
221 characteristics identified in the table(s) below do not raise different safety and effectiveness
222 questions, and how the subject device is substantially equivalent to the predicate(s).

223
224 **Table 7 – Predicate Comparison General Descriptive Information**
225

System Characteristics	Subject Device	Primary Predicate	Additional Predicate
Intended use	<i>Arthrodesis and fracture fixation</i>	<i>Arthrodesis</i>	<i>Fracture fixation</i>
Classification/Product code			
Target population	<i>Adults</i>		
Anatomical site of use	<i>Foot</i>	<i>Mid foot</i>	<i>Forefoot</i>
Provided sterile/non-sterile			
Sterilization method			
Shelf life			
Packaging			

226

¹⁴ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-and-performance-based-pathway>.

¹⁵ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-non-spinal-metallic-bone-screws-and-washers-performance-criteria-safety-and-performance>.

¹⁶ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orthopedic-fracture-fixation-plates-performance-criteria-safety-and-performance-based-pathway>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

227
228

Table 8 – Predicate Comparison Plate Descriptive Information

Plate Description	Subject Device	Primary Predicate	Additional Predicate
Representative image or photograph of component			
Anatomical site of use	<i>Proximal humerus</i>	<i>Humerus</i>	<i>Long bones</i>
Materials	<i>CP Ti Grade 4</i>	<i>Stainless steel</i>	
Any standards to which the materials conform	<i>ASTM F67</i>	<i>ASTM F138</i>	
General plate shapes	<i>Anatomic specific</i>	<i>Straight plate</i>	
Number of holes	<i>12</i>	<i>8</i>	
Hole dimensions	<i>5.2mm diameter holes</i>	<i>6mm diameter holes</i>	
Locking mechanism if applicable	<i>Locking screws mate directly with threads on the plate</i>	<i>Non-locking</i>	<i>Locking caps</i>
Screw placement trajectory	<i>Fixed angle locking screws; non-locking screws inserted in a 10 degree polyaxial cone</i>	<i>orthogonal</i>	<i>Fixed angle non-locking</i>
Plate width range	<i>8mm – 30mm</i>	<i>8mm – 12mm</i>	
Plate length range	<i>50mm – 150mm</i>	<i>80mm</i>	
Plate thickness range	<i>3mm – 3.5mm</i>	<i>2.5mm</i>	
Compatible screw sizes	<i>3.5mm</i>	<i>4.0mm</i>	<i>3.5mm</i>
Compatible screw types	<i>Locking, non-locking</i>	<i>Variable angle locking screw</i>	

229
230
231

Table 9 – Predicate Comparison Stand-Alone Screw Descriptive Information

Screw Description	Subject Device	Primary Predicate	Additional Predicate
Representative image or photograph of component			
Materials	<i>Stainless steel</i>	<i>Ti-6Al-4V titanium alloy; Cobalt-Chrome</i>	
Any standards to which the materials conform	<i>ASTM F138</i>	<i>ASTM F136; ASTM F1537</i>	
Type of screw	<i>Headless screw</i>	<i>Cancellous screw</i>	<i>Snap-off screw</i>
If cannulated: cannula diameter	<i>1.5mm</i>		
Screw length range	<i>8mm – 60mm</i>		

Contains Nonbinding Recommendations

Draft – Not for Implementation

Screw Description	Subject Device	Primary Predicate	Additional Predicate
Length of threaded region range	<i>5mm – 50mm</i>		
Minor screw diameter range	<i>2.5mm</i>		
Major screw diameter range	<i>3.5mm</i>	<i>3.2mm</i>	
Thread pitch range	<i>1.0mm</i>	<i>1.25mm</i>	

Table 10 – Predicate Comparison Washer Descriptive Information

Washer/Bolt Nut Description	Subject Device	Primary Predicate	Additional Predicate
Representative image or photograph of component			
Materials	<i>CP Ti Grade 4</i>	<i>Stainless steel</i>	
Any standards to which the materials conform	<i>ASTM F67</i>	<i>ASTM F138</i>	
Inner diameter range	<i>3mm – 6mm</i>		
Outer diameter range	<i>5mm – 10mm</i>		
Thickness	<i>0.5mm</i>		
Compatible screws	<i>2.7mm – 7.5mm</i>		

- The materials used for bone plates and bone screws impact the mechanical performance of these devices. If your plate and/or screw components are manufactured from different materials than the predicates you have identified, or use different manufacturing methods or processing steps, additional material characterization may be requested, such as fatigue performance of the plate, or mechanical evaluations of the plate/screw interface. We recommend you submit a Pre-Submission to discuss the testing plans with FDA. For more information about Pre-Submissions and the Q-Submission program, refer to the FDA guidance document entitled “[Requests for Feedback on and Meetings for Medical Device Submissions: The Q-Submission Program](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program).”¹⁷
- Metallic fracture fixation hardware components that are generally in contact with components made of dissimilar metals may result in galvanic corrosion. Additionally, novel materials may raise questions regarding corrosion in that corrosion may cause premature failure of the device and adverse biological reactions. If your plate or screw system contains metallic components that are different from the predicate device, or if the combination of metals in the subject system is different or has known susceptibility to corrosion (e.g., connections of nitinol and stainless steel components), additional information may be necessary to demonstrate that corrosion susceptibility over the entire surface of the final finished device and interfacing components is equal to or less than that measured in a legally marketed device with the same intended use. ASTM F2129 *Standard Test Method for Conducting Cyclic Potentiodynamic Polarization*

¹⁷ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

257 *Measurements to Determine the Corrosion Susceptibility of Small Implant Devices* may
258 be appropriate to analyze corrosion susceptibility of your device. We recommend you
259 submit a Pre-Submission to discuss the testing plans with FDA. For more information
260 about Pre-Submissions and the Q-Submission program, refer to the guidance “[Requests
261 for Feedback and Meetings for Medical Device Submissions: The Q-Submission
262 Program](#).”¹⁸

263 **D. Labeling**

264 The premarket notification must include proposed labeling in sufficient detail to satisfy the
265 requirements of 21 CFR 807.87(e). Proposed labels and labeling, sufficient to describe the bone
266 plates, screws, and washers, their intended use, and the directions for use should be provided.
267

268 As prescription devices, bone plates, screws, and washers are exempt from having adequate
269 directions for use under section 502(f)(1) of the Federal Food, Drug and Cosmetic Act (FD&C
270 Act)) as long as the conditions in 21 CFR 801.109 are met. For instance, labeling should include
271 adequate information for practitioner use of the device, including indications, effects, routes,
272 methods, frequency and duration of administration and any relevant hazards, contraindications,
273 side effects and precautions. (21 CFR 801.109(d)).
274

275 In addition to requirements in 21 CFR part 801, labeling should include the following
276 information:
277

- 278 • Device description (including material and sterility status);
- 279 • Device use (including single-use/reusable, intended users or specific patient populations);
- 280 • Contraindications (e.g., active infection, inability to comply with post-operative weight
281 bearing instructions, inadequate bone stock or poor blood supply)
- 282 • Warnings (e.g., not to use the device across an active growth plate for devices indicated
283 for pediatric use);
- 284 • MR safety information (refer to Section J);
- 285 • Cleaning and sterilization instructions, if applicable (refer to Sections E and F); and
- 286 • Removal instructions (particularly for devices indicated for pediatric use).
287

288 Additionally, since plating systems can contain many different plate types and components for
289 creating a fracture fixation construct, we recommend that you provide information in the labeling
290 to aid the surgeon in proper construct selection (e.g., material labeling for plates of the identical
291 geometry or comparative performance information).
292

293 For plate(s) made of anisotropic materials, if the submission includes labeling that instructs users
294 to contour plates to fit varying patient anatomies, we recommend also including in the 510(k)

¹⁸ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

295 submission testing and/or justification demonstrating that the plate(s) maintains adequate
296 strength following such bending. This is further discussed in Section IV.K.1 below.

297 **E. Sterility**

298 Significance: Bone plates, screws, washers, and patient contacting instrumentation should be
299 adequately sterilized to minimize infections and related complications.

300
301 Recommendation: For bone plates, screws, and washers, and instruments labeled as sterile, we
302 recommend that you provide information for the finished device in accordance with FDA’s
303 guidance “[Submission and Review of Sterility Information in Premarket Notification \(510\(k\)\)](#)
304 [Submissions for Devices Labeled as Sterile](#).”¹⁹

305 **F. Reprocessing (including single-use devices provided non- 306 sterile and intended for sterile processing)**

307 Significance: Many of the patient contacting instruments associated with bone plates, screws,
308 and washers are reused, and should be adequately cleaned and sterilized between uses to
309 minimize infections and prevent device degradation. Bone plates, screws, and washers can also
310 be single-use medical devices initially supplied as non-sterile to the user and necessitate the user
311 to process (clean and sterilize) the device prior to its use.

312
313 Cleaning instructions in the labeling should clearly identify their applicability for reprocessing
314 soiled reusable instruments or their applicability to new and uncontaminated implants and
315 instruments prior to sterilization.

316
317 Recommendation: Instructions on how to reprocess a reusable device or process a single-use
318 device that is provided non-sterile to the user are critical to ensure that a device is appropriately
319 prepared for its initial and/or subsequent uses and should be included in the labeling.

320
321 Instructions for cleaning should be designed and validated for the type of contamination
322 anticipated on the device, based on its intended use. Accordingly, there may be separate,
323 dedicated cleaning instructions; for new, uncontaminated single-use devices prior to sterilization,
324 as well as separate, dedicated instructions for routine cleaning of contaminated reusable medical
325 instruments prior to sterilization. Single-use devices such as implants, should be cleaned
326 separately from soiled reusable devices to prevent cross contamination.

327
328 The removal of all residues of manufacturing materials such as lubricants, oils, particulates, and
329 other debris should occur during the manufacturing process, as part of Good Manufacturing
330 Practices (see 21 CFR Part 820). Additionally, health care facilities are unlikely to have the
331 capacity, materials, or adequately trained personnel to remove residues of manufacturing
332 materials from medical devices. Validated cleaning steps should be performed for removing
333 manufacturing contaminants from your implants at the site of manufacture, in accordance with
334 the Quality System Regulation, 21 CFR 820.70(h).

¹⁹ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

335 For recommendations regarding the development and validation of reprocessing parameters and
336 the reprocessing instructions in your proposed device labeling, refer to FDA’s guidance
337 [“Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling.”](#)²⁰
338

339 The following list includes some additional considerations for reprocessing instructions that are
340 included in the labeling for bone plates, screws, and washers provided non-sterile to the end user:
341

342 ○ Final rinse water quality should include specifications qualified for the device’s
343 intended use. For example, Critical Water, as currently defined by AAMI TIR34:
344 *Water for the Reprocessing of Medical Devices*, is recommended to address various
345 concerns for implantable devices.

346 ○ We recommend that the labeling include a statement to warn against use of devices
347 that may have become damaged or contaminated. For example: *“If the device has*
348 *become damaged or contaminated, it should NOT be reprocessed and should be*
349 *properly disposed of.”*

350 If the labeling instructs the end user to reprocess (sterilize, or clean and sterilize)
351 “opened-but-unused” devices, validated instructions (for sterilization, or cleaning and
352 sterilization) should be included in the labeling. In these circumstances, we
353 recommend that labeling designated for “Opened-but-Unused” products include
354 comprehensive instructions that:

355 1. explicitly define “contaminated” and characterize the conditions under which
356 a device would be considered “unused.”

357 Note: FDA considers that:

- 358 • a statement such as "no contamination with body fluids" is not adequate,
359 as not all contamination is necessarily visible;
- 360 • a device which has been introduced to the sterile field, even if “unused,”
361 may be contaminated as such items may have been subjected to
362 aerosolized contaminants or other sources of contamination; and
- 363 • all handling should be considered a potential source of contamination.

364 2. provide validated reprocessing instructions for “Opened-but-Unused” product
365 that are consistent with definitions as recommended above.
366

367 ○ We recommend that reprocessing validation activities for bone plates, screws, and
368 washers account for the use of sterilization trays, and instructions in the labeling
369 should be consistent with these validation activities (e.g., if trays were not stacked

²⁰ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reprocessing-medical-devices-health-care-settings-validation-methods-and-labeling>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

370 during the validation activities, then a “Do Not Stack Trays” warning should be
371 included).

372 We recommend that information about the sterilization trays be included in the
373 submission for bone plates, screws, and washers. If a third party, general use
374 sterilization tray is utilized, the 510(k) number should be provided. For dedicated
375 sterilization trays that are unique to a particular orthopedic system, adequate device
376 description information should be provided, including an explanation of the tray
377 dimensions, material, and load configuration and contents. If you intend to leverage
378 information from a previously validated worst-case system, you should also include
379 an explanation of how the challenge device is applicable to the subject system, in
380 accordance with FDA-recognized consensus standard, ANSI/AAMI/ISO 17665-1:
381 *Sterilization of health care products – Moist heat – Part 1.*

382 **G. Pyrogenicity**

383 Significance: Pyrogenicity testing is used to help protect patients from the risk of febrile
384 reaction due to gram-negative bacterial endotoxins and/or chemicals that can leach from a
385 medical device (e.g., material-mediated pyrogens).
386

387 Recommendation: To address the risks associated with the presence of bacterial endotoxins,
388 bone plates, screws, and washers provided sterile should meet pyrogen limit specifications by
389 following the recommendations outlined in FDA’s guidance “[Submission and Review of
390 Sterility Information in Premarket Notification \(510\(k\)\) Submissions for Devices Labeled as
391 Sterile.](#)”²¹ You should also follow the recommendations in “[Guidance for Industry Pyrogen and
392 Endotoxins Testing: Questions and Answers.](#)”²² To address the risks associated with material-
393 mediated endotoxins, follow the recommendations in FDA’s guidance “[Use of International
394 Standard ISO-10993-1, 'Biological Evaluation of Medical Devices Part 1: Evaluation and
395 Testing.](#)”²³
396

397 For devices intended to be labeled as “non-pyrogenic,” we recommend that both bacterial
398 endotoxins and material-mediated pyrogens be addressed.

399 **H. Shelf Life and Packaging**

400 Significance: Package shelf life (stability) and package integrity (performance) testing is
401 conducted to support the proposed package shelf life (expiration date) and performance. Testing
402 should also be conducted to evaluate any changes to device performance or functionality.
403

404 Recommendation: For devices provided sterile, you should provide a description of the
405 packaging, including how it will maintain the device’s sterility, a description of the package

²¹ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled>.

²² <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers>.

²³ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

406 integrity test methods, but not the package integrity test data. We recommend that package
407 integrity test methods include simulated distribution and associated package integrity testing, as
408 well as simulated (and/or real time) aging and associated seal strength testing, to validate
409 package integrity and shelf life claims. We recommend you follow the methods described in ISO
410 11607-1 *Packaging for terminally sterilized medical devices – Part 1: Requirements for*
411 *materials, sterile barrier systems and packaging systems* and ISO 11607-2 *Packaging for*
412 *terminally sterilized medical devices – Part 2: Validation requirements for forming, sealing and*
413 *assembly processes*.

414
415 With respect to evaluating the effects of aging on device performance or functionality, shelf life
416 studies should evaluate the critical physical and mechanical properties of the device to ensure it
417 will perform adequately and consistently during the entire proposed shelf life. To evaluate device
418 functionality, we recommend that you assess each of the bench tests described in Section K and
419 repeat all tests that evaluate design components or characteristics that are potentially affected by
420 aging.

421
422 We recommend that you provide a summary of the test methods used for your shelf life testing,
423 results, and the conclusions drawn from your results. If you use devices subject to accelerated
424 aging for shelf life testing, we recommend that you specify the way in which the devices were
425 aged and provide a rationale to explain how the results of shelf life testing, based on accelerated
426 aging, are representative of the results if the device were aged in real time. We recommend that
427 you age your devices as per ASTM F1980 *Standard Guide for Accelerated Aging of Sterile*
428 *Barrier Systems for Medical Devices* and specify the environmental parameters established to
429 attain the expiration date. For devices or components containing polymeric materials or coatings,
430 you should conduct testing on real-time aged samples to confirm the results of the accelerated
431 aging study. This testing should be conducted in parallel with 510(k) review and clearance, with
432 results documented to file in the design history file (i.e., the complete test reports do not need to
433 be submitted to FDA).

434 **I. Biocompatibility**

435 Significance: Bone plates, screws, washers, and accompanying surgical instrumentation contain
436 patient-contacting materials, which, when used for their intended purpose, (i.e., contact type and
437 duration), may induce a harmful biological response.

438
439 Recommendation: You should determine the biocompatibility of all patient-contacting materials
440 present in your device (this includes implants and device-specific instrumentation). If your
441 device(s) in its final finished form is identical in chemical composition, manufacturing, and
442 processing methods, and any differences in geometry or surface properties are not expected to
443 adversely impact the biological response compared to a legally marketed bone plate(s), screw(s),
444 washer(s), or instrument(s) with a history of successful use, you may reference previous testing
445 experience, or the literature, if appropriate. For metallic devices it may be appropriate to
446 reference a recognized consensus standard, while for polymeric devices, a Letter of
447 Authorization (LOA) for a device Master File (MAF) could be provided. You should refer to the
448 following FDA webpage for additional information on using device MAFs:
449 <https://www.fda.gov/medical-devices/premarket-approval-pma/master-files>. In addition to the

Contains Nonbinding Recommendations

Draft – Not for Implementation

450 device material information, you should provide information to demonstrate that the subject
451 device is identical to a legally marketed device with respect to manufacturing material
452 formulations, processes, packaging, and sterilization methods (if applicable) in its final finished
453 form. Attachment F of the FDA guidance document, “[Use of International Standard ISO 10993-
454 1, ‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk
455 management process’](#),”²⁴ includes example documentation language that may be utilized.
456

457 If you are unable to identify a legally marketed predicate device with the same nature of contact
458 and contact duration that uses the same materials and manufacturing process as used in your
459 device, we recommend that you conduct and provide a biocompatibility evaluation as
460 recommended in FDA’s guidance “[Use of International Standard ISO-10993-1, ‘Biological
461 evaluation of medical devices - Part 1: Evaluation and testing within a risk management
462 process’](#).”²⁵ The evaluation should explain the relationship between the identified
463 biocompatibility risks, the information available to mitigate the identified risks, and any
464 knowledge gaps that remain. You should then identify any biocompatibility testing or other
465 evaluations that were conducted to mitigate any remaining risks. We recommend that you
466 consider the recommendations in this guidance, which identifies the types of biocompatibility
467 assessments that should be considered and recommendations regarding how to conduct related
468 tests.
469

470 Per ISO 10993-1 *Biological evaluation of medical devices – Part 1: Evaluation and testing
471 within a risk management process* and Attachment A of FDA’s guidance on ISO-10993-1, bone
472 plates, screws, and washers are implant devices in contact with tissue/bone for a permanent
473 contact duration. Therefore, the following endpoints should be addressed in your
474 biocompatibility evaluation:
475

- 476 • cytotoxicity;
 - 477 • sensitization;
 - 478 • irritation or intracutaneous reactivity;
 - 479 • acute systemic toxicity;
 - 480 • material mediated pyrogenicity;
 - 481 • subacute/subchronic toxicity;
 - 482 • genotoxicity;
 - 483 • implantation;
 - 484 • chronic toxicity; and
 - 485 • carcinogenicity.
- 486

487 For device-specific, patient-contacting device instrumentation in contact with tissue/bone for a
488 limited contact duration, the following endpoints should be addressed in your biocompatibility
489 evaluation:
490

²⁴ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-international-standard-iso-10993-1-biological-evaluation-medical-devices-part-1-evaluation-and->

²⁵ Ibid.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 491 • cytotoxicity;
- 492 • sensitization;
- 493 • irritation or intracutaneous reactivity;
- 494 • acute systemic toxicity; and
- 495 • material mediated pyrogenicity.

496 **J. Magnetic Resonance (MR) Compatibility for Passive** 497 **Implants**

498 Significance: MR imaging of patients with bone plates, screws, and washers poses the following
499 potential hazards:

- 500 • movement of the implant, resulting in tissue damage or displacement of the device;
- 501 • heating of the tissue surrounding the implant and subsequent tissue damage; and/or
- 502 • image artifacts that may render the MR images uninterpretable or misleading.

503
504 Recommendation: We recommend that you address the issues affecting safety and compatibility
505 of your device in the MR environment as described in the FDA guidance “[Testing and Labeling](#)
506 [Medical Devices for Safety in the Magnetic Resonance \(MR\) Environment](#).”²⁶

507
508 For devices anticipated for use in the MR environment that have not been evaluated for safety in
509 the MR environment, we recommend you follow FDA’s recommendations in section VIII.D. of
510 the above referenced guidance document.

511
512 If you would like to market bone plates, screws, or washers of various sizes and shapes as “MR
513 Conditional,” then we recommend you follow our recommendations in the FDA guidance,
514 “[Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance \(MR\) Environment](#)
515 [for Multi-Configuration Passive Medical Devices](#).”²⁷

516 **K. Non-Clinical Testing**

517 The 510(k) submission should include information to demonstrate that the subject device
518 provides substantially equivalent fixation of a fracture site. We recommend that you conduct the
519 testing recommended below to evaluate the material and performance characteristics of your
520 worst-case device in its final finished form. If your plate, screw, or washer system is indicated
521 for use in multiple anatomical locations or if the system encompasses a large variety of device
522 designs, there may be more than one worst-case device that should be supported with mechanical
523 performance data.

524
525 A sample size of five (5) units has historically been accepted as the minimum for bench testing.
526 Additional issues in testing (e.g., large inter-sample variability) or device design may warrant a
527 larger sample size.

²⁶ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-and-labeling-medical-devices-safety-magnetic-resonance-mr-environment>.

²⁷ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessment-radiofrequency-induced-heating-magnetic-resonance-mr-environment-multi-configuration>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

528
529 For information on the recommended content and format of test reports for the testing described
530 in this section, refer to FDA’s guidance, “[Recommended Content and Format of Non-Clinical](#)
531 [Bench Performance Testing Information in Premarket Submissions](#).”²⁸
532

533 For the FDA-recognized consensus standards identified below, supplemental documentation to
534 support a Declaration of Conformity is likely necessary as discussed in FDA’s guidance,
535 “[Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical](#)
536 [Devices](#),”²⁹ as these standards contain variable methods and do not include acceptance criteria
537 for all testing recommended in this guidance. The supplemental documentation should include
538 the items specified in the report section of each testing annex in the consensus standard (and
539 listed below in Appendices A and B) used to support the premarket submission. Acceptance
540 criteria, if not included in the applicable FDA-recognized consensus standard(s), should be
541 provided with a supporting rationale to justify how the performance testing results support a
542 determination of substantial equivalence. We recommend that you can provide a comparison of
543 the subject device test results to the test results of a legally marketed predicate device with the
544 same intended use, in a tabular format such as the examples in Appendices A and B.
545

546 The following sections describe the recommended mechanical performance testing endpoints for
547 bone plates and screws. When a plating system’s overall construct and plate designs are similar
548 to the identified predicate, individual analysis of the worst-case plate and screw components as
549 listed below may be sufficient to establish substantial equivalence of the construct. When the
550 overall subject construct differs in fixation method or raises concerns about strength or stability
551 at the fracture site, additional construct evaluations such as bench testing or *in vivo* data may be
552 needed to demonstrate substantial equivalence. Additional endpoints or testing information may
553 be needed depending on the device design and comparison to the predicate device(s). Devices
554 which are made from polymers, metals, or metallic alloys with different properties compared to
555 the identified predicates, especially resorbable materials, may warrant additional performance
556 information such as component interface analysis (e.g., wear, corrosion) or fatigue strength
557 analysis. Technological characteristics that appear to create worse mechanical performance
558 compared to the identified predicates may warrant additional information to demonstrate
559 equivalent fracture fixation in construct strength, construct stiffness and fatigue performance.
560

561 Submissions for devices made of anisotropic materials should address shear strength of the
562 devices and risk for crack propagation through additional testing and/or scientific justification.
563 When evaluating a device(s) containing fibers, such as CFR PEEK, device parameters including
564 percent fiber used, length of fibers (average and distribution), fiber direction, and sizing agent
565 (for interfacial adhesion between fiber and polymer) should be taken into consideration as these
566 parameters can impact the mechanical performance of the device. Specific recommendations for
567 plate(s) made of anisotropic materials are discussed in Section VI.K.1 below.

²⁸ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recommended-content-and-format-non-clinical-bench-performance-testing-information-premarket>.

²⁹ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612

1. Plate Mechanical Performance

Significance: Loss of fracture reduction or construct stiffness can cause incomplete or absent osteosynthesis leading to device failure and revision surgery. Mechanical performance testing of plates provides assurance of the device’s ability to perform as intended.

Recommendation: Single cycle bend testing should be conducted on the worst-case subject plate in the worst-case load bearing region. When assessing the mechanical performance of plates with a worst-case structurally critical region (that can physically fit between the loading rollers of a four-point bend test), we recommend performing testing per ASTM F382 *Standard Specification and Test Method for Metallic Bone Plates*. The worst-case design selection should consider plate thickness, second moment of area, length, and overall shape. Depending on the particular plate geometry and dimensions, modifications to the test setup outlined in ASTM F382, with appropriate justification, could be considered. Outcomes for the single cycle (quasi-static) bend testing should include the bending structural stiffness and the bending strength.

To ensure the test results can be adequately evaluated, we recommend you provide testing information per ASTM F382 for subject and predicate tests in tabular format, identifying any differences in test methods and providing a justification for why these differences do not impact the comparability of results. See Appendix A, Example Table of Plate Test Methods and Data Summary, for an example of how test summary information could be organized.

Plates with similar design features and materials to predicate devices typically do not warrant fatigue bend testing per ASTM F382. However, devices with differences in technological features compared to traditional plating systems (e.g., different material selection, complex designs, plate modularities) may warrant fatigue testing to demonstrate substantial equivalence. Plates with their worst-case structurally critical region present in the uniform portion of the plate shaft are expected to show similar trends when comparing static performance and fatigue performance (if applicable).

If you use an alternative method to ASTM F382, the following should be taken into account when designing the test setup to determine component or construct equivalence: the worst-case clinically relevant loading, clinically relevant loading modes (e.g., axial compression, bending, torsion), differences in material properties, and differences in dimensions and geometry of the subject and predicate devices.

For a plate(s) made of anisotropic materials, if bending/contouring is not explicitly discouraged in the labeling, the submission should include additional testing and/or a scientific justification to confirm the plate(s) is able to maintain mechanical performance following worst-case contouring consistent with the

Contains Nonbinding Recommendations

Draft – Not for Implementation

instructions provided in the labeling and common clinical practice.

2. Screw Mechanical Performance

Significance: Inadequate mechanical performance can cause screws to fracture during insertion or during healing. Torsional strength analysis provides assurance of strength. Loss of fixation can lead to premature failure of the screws or backout causing pain from increased prominence. Pullout strength analysis provides assurance of fixation strength.

Recommendation: When assessing the mechanical performance of screws, we recommend performing 1) insertion/removal torque testing, 2) torsional strength testing, and 3) pullout strength testing per ASTM F543 *Standard Specification and Test Methods for Metallic Medical Bone Screws*. For screws with technological characteristics (e.g., screw thread designs) that conform to FDA-recognized consensus standards (e.g., ASTM F543), an engineering analysis using the thread geometry, based upon the equation described by Chapman, et al,³⁰ can also be utilized to demonstrate equivalence for pullout strength in lieu of testing.

Insertion/removal torque testing, torsional strength testing, and pullout strength testing should each be conducted on the corresponding worst-case screws. The worst-case design selection should consider critical parameters such as major/minor screw diameters, thread pitch and trailing angles, polar moment of inertia, thread length, flute design. Reported results for torsional strength testing should include the torsional yield strength and maximum load. Reported results for insertion/removal torque testing should include, respectively, the maximum recorded insertion and removal torques. Reported results for pullout testing should include the maximum load recorded during screw pullout. If pullout testing is not physically performed, then insertion and removal torque testing can be leveraged to confirm that the threads are adequately designed and attached to the screw core diameter.

To ensure the test results can be adequately evaluated, we recommend you provide reportable information per ASTM F543 for subject and predicate tests in tabular format, identifying any differences in test methods and providing a justification for why these differences do not impact the comparability of results. See Appendix B of this guidance, Example Table of Screw Test Methods and Data Summary, for an example of how test summary information can be organized.

Screws with traditional characteristics (e.g., fully threaded) and materials (e.g., stainless steel, titanium alloy) as described in the consensus standards referenced in this guidance typically do not warrant additional evaluation beyond the test

³⁰ Chapman, J. R., et al, Factors Affecting the Pullout Strength of Cancellous Bone Screws. *J Biomech Eng* 1996; 118(3), 391-8. doi:10.1115/1.2796022.)

Contains Nonbinding Recommendations

Draft – Not for Implementation

655 methods described in ASTM F543. However, screws with differences in
656 technological characteristics compared to traditional screws (e.g., different
657 material selection, complex designs, modularities) may warrant additional static
658 and fatigue testing to demonstrate substantial equivalence. We recommend you
659 refer to ASTM F1264 *Standard Specification and Test Methods for*
660 *Intramedullary Fixation Devices* for information on fatigue three- or four-point
661 bending evaluation methods for screws.

662
663 If you use an alternative method to ASTM F543, the following should be taken
664 into account when designing the test setup: worst-case clinically relevant loading
665 conditions, differences in material properties, and differences in dimensions and
666 geometry of the subject and predicate devices.

3. Computational Modeling and Engineering Analysis

667 Significance: Computational modeling (e.g., finite element analysis) and
668 engineering analysis (e.g., dimensional comparison and theoretical calculation of
669 mechanical performance based on empirical models) can be used as an alternative
670 to demonstrate that the mechanical behavior of the worst-case subject plates and
671 screws are expected to be equal to or better than the predicate devices.
672

673 Recommendation: If computational modeling or engineering analysis is used to
674 address some or all of the endpoints identified in Sections K. 1. and K. 2.,
675 modeling should be performed on the worst-case plate(s) and screw(s). Specific
676 subject plate geometries, such as changes in geometries over the plate length,
677 curvatures, and differences in material, can make static and fatigue comparisons
678 difficult to account for in engineering analysis alone. Therefore, we recommend
679 validation testing to confirm the accuracy of your computational modeling,
680 especially for unique design features/components interfaces.
681

682
683 If no physical testing of specimens is conducted, your computational modeling
684 and/or engineering analysis should address all endpoints identified in Sections K.
685 1. and K. 2. Refer to FDA’s guidance “[Reporting of Computational Modeling
686 Studies in Medical Device Submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-computational-modeling-studies-medical-device-submissions)”³¹ for additional details regarding model
687 validation and reporting numerical simulations. Specifically, refer to Subject
688 Matter Appendix II of the referenced guidance for details concerning
689 computational solid mechanics.
690

691
692 An engineering analysis can be used in lieu of bench testing to support substantial
693 equivalence of the yield strength and structural bending stiffness of a plate if the
694 predicate plate dimensions and material properties (modulus and yield strength)
695 are known, and if the predicate plate is manufactured utilizing the same device
696 material and manufacturing materials and processes as the subject device. The

³¹ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-computational-modeling-studies-medical-device-submissions>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

697 second moment of area and material properties at multiple cross-sections for both
698 the subject and predicate plates can be used to calculate the worst-case theoretical
699 structural bending stiffness and yield moment of each plate.
700

701 Similarly, for screws, an engineering analysis can be used in lieu of bench testing
702 to support substantial equivalence of a screw's torsional performance if the
703 predicate screw dimensions (e.g., core diameter, cannulation diameter) and
704 material properties (modulus and yield strength) are known and if the predicate
705 screw is manufactured utilizing the same material and manufacturing processes as
706 the subject device.
707

708 As referenced above in Section K.2, an engineering analysis based upon the
709 equation described by Chapman, et al, can be used in lieu of testing to evaluate
710 pullout strength of the screw if the predicate screw dimensions are known, and if
711 the material ultimate shear stress (S) and failure modes of the bone foam substrate
712 are equivalent between the subject and predicate devices. For example, a material
713 ultimate shear stress value of 3.395 MPa can be used to represent 20 pcf bone
714 foam in your analysis. Note that for this analysis to be appropriate, the
715 instrumentation identified in the associated surgical technique manual should
716 allow for close to idealized thread engagement. If this assumption is not accurate
717 for your scenario, then the identified engineering analysis may not be appropriate
718 for the assessment of the subject device.
719

720 For all screws, extract the relevant dimensions below (i.e., screw major diameter,
721 screw minor diameter, screw pitch, and axial thread length). These dimensions
722 will be used to quantify thread engagement and calculate the theoretical pullout
723 strengths for the smallest axial thread lengthened screws in the device system
724 using the following equation:
725

$$726 \quad F_s = S * A = \{S * L * \pi * D_{major} * TSF\}$$

727
728 F_s = predicted shear failure force (N)

729 S = material ultimate shear stress (MPa)

730 A = thread shear area (mm²)

731 L = axial thread length (mm) including only threads that have the nominal major
732 diameter where complete purchase is expected (e.g., excluding the screw tip) of
733 thread engagement in material

734 D_{major} = major diameter (mm)

735 TSF = Thread Shape Factor (dimensionless) = $(0.5 + 0.57735 d/p)$

736 d = thread depth (mm) = $(D_{major} - D_{minor})/2$

737 D_{minor} = minor (root) diameter (mm)

738 p = thread pitch (mm)
739

740 A justification should be provided to support why the evaluated screws selected
741 are worst case and also for each variable used in the Chapman analysis (e.g., bone

Contains Nonbinding Recommendations

Draft – Not for Implementation

742 foam per ASTM F1839). Axial pullout performance is heavily influenced by
743 amount of interface and the failure mechanism at the interface with bone foam.
744 Factors such as decreasing outer diameter and decreasing axial thread length may
745 help identify the worst case.

746
747 Dimensions used for calculations should be clearly listed for each theoretical
748 outcome. Dimensional values used in this calculation should be consistent with
749 the values listed on the screw engineering drawings.

750 **L. Non-Clinical Animal and/or Clinical Performance Testing**

751 Non-clinical animal studies³² and/or clinical evidence are generally unnecessary for most bone
752 plates and screws; however, such testing may be requested in situations such as the following:
753

- 754 • indications for use dissimilar from legally marketed devices of the same type;
- 755 • new technology, i.e., technology different from that used in legally marketed devices of
756 the same type (e.g., dynamic or flexible fixation systems that differ in stiffness or
757 strength to other predicates), yet does not raise different questions of safety or
758 effectiveness; or
- 759 • cases where engineering and/or animal testing raise issues that warrant further evaluation
760 with clinical evidence.

761
762 We encourage manufacturers to take advantage of the Q-Submission Program to ensure that the
763 animal study protocol addresses safety concerns and contains elements which are appropriate for
764 a regulatory submission. For example, animal studies to determine a device’s safety must be
765 performed under the Good Laboratory Practice (GLP) regulation in 21 CFR Part 58. In addition,
766 if you are proposing to use a non-animal testing method that you believe is suitable, adequate,
767 validated, and feasible, we recommend that you discuss the proposal using the Q-Submission
768 Program. We will consider if such an alternative method could be assessed for equivalency to an
769 animal test method. For details on the Q-Submission Program, refer to the guidance “[Requests
770 for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program](#).”³³
771

772 We will consider alternatives to clinical testing when the proposed alternatives are supported by
773 an adequate scientific rationale. If a clinical study is needed to demonstrate substantial
774 equivalence, i.e., conducted prior to obtaining 510(k) clearance of the device, the study must be
775 conducted under the Investigational Device Exemptions (IDE) regulation, 21 CFR Part 812.
776 Generally, we believe bone plates and screws addressed by this guidance document are
777 significant risk devices subject to all requirements of 21 CFR 812. See the FDA Guidance titled,

³² FDA supports the principles of the “3Rs,” to reduce, refine, and replace animal use in testing when feasible. We encourage sponsors to consult with us if they wish to use a non-animal testing method they believe is suitable, adequate, validated, and feasible. We will consider if such an alternative method could be assessed for equivalency to an animal test method.

³³ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

778 [“Significant Risk and Nonsignificant Risk Medical Device Studies.”](#)³⁴ In addition to the
779 requirements of 21 CFR 812, sponsors of such trials should comply with the regulations
780 governing institutional review boards (21 CFR Part 56) and informed consent (21 CFR Part 50).
781

782 When data from clinical investigations conducted outside the U.S. are submitted to FDA for
783 these devices, the requirements of 21 CFR 812.28 may apply.³⁵ 21 CFR 812.28 outlines the
784 conditions for FDA acceptance of clinical data from investigations conducted outside the U.S.
785 when submitted to support premarket submissions. For more information, see the FDA guidance
786 [“Acceptance of Clinical Data to Support Medical Device Applications and Submissions:
787 Frequently Asked Questions.”](#)³⁶
788

789 In some cases, “real-world data” (RWD) may be used to support expansion of indications,
790 changes in surgical technique, or changes in design/prominence for a device for which 510(k)
791 clearance has already been obtained. Whether the collection of RWD for a legally-marketed
792 device requires an IDE depends on the particular facts of the situation. Specifically, if a cleared
793 device is being used in the normal course of medical practice, an IDE would likely not be
794 required. For additional information regarding this topic, please refer to the FDA Guidance
795 entitled [“Use of Real-World Evidence to Support Regulatory Decision-Making for Medical
796 Devices.”](#)³⁷

797 **V. Modifications (Devices subject to 510(k))**

798 In accordance with 21 CFR 807.87(a)(3), a device change or modification “that could
799 significantly affect the safety or effectiveness of the device” or represents “a major change or
800 modification in the intended use of the device” requires a new 510(k).³⁸ The changes or
801 modifications listed below are examples of changes that may require submission of a new

³⁴ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/significant-risk-and-nonsignificant-risk-medical-device-studies>.

³⁵ This applies to data from clinical investigations that began on or after February 21, 2019, and are submitted to support a premarket submission, including IDEs, premarket approval applications (PMAs), and 510(k)s.

³⁶ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/acceptance-clinical-data-support-medical-device-applications-and-submissions-frequently-asked>.

³⁷ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices>.

³⁸ Section 3308 of the Food and Drug Omnibus Reform Act of 2022, Title III of Division FF of the Consolidated Appropriations Act, 2023, Pub. L. No. 117-328 (“FDORA”), enacted on December 29, 2022, added section 515C “Predetermined Change Control Plans for Devices” to the FD&C Act (section 515C). Under section 515C, FDA can approve or clear a predetermined change control plan (PCCP) for a device that describes planned changes that may be made to the device and that would otherwise require a supplemental premarket approval application or premarket notification. For example, section 515C provides that a supplemental premarket approval application (section 515C(a)) or a premarket notification (section 515C(b)) is not required for a change to a device if the change is consistent with a PCCP that is approved or cleared by FDA. Section 515C also provides that FDA may require that a PCCP include labeling for safe and effective use of a device as such device changes pursuant to such plan, notification requirements if the device does not function as intended pursuant to such plan, and performance requirements for changes made under the plan. If you are interested in proposing a PCCP in your marketing submission, we encourage you to submit a Pre-Submission to engage in further discussion with CDRH. See FDA’s guidance [“Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program.”](#)

Contains Nonbinding Recommendations

Draft – Not for Implementation

802 510(k). Note that this list is not exhaustive but provides examples of modifications that are likely
803 to require submission of a new 510(k). For additional details, please see FDA guidance,
804 [“Deciding When to Submit a 510\(k\) for a Change to an Existing Device.”](#)³⁹
805

806 Such changes or modifications include:
807

- 808 • The addition of a thinner or thicker bone plate, or screws with lower pullout strength than
809 a legally marketed predicate device – FDA considers this change to be a significant
810 change in design. These types of changes could significantly affect the safety and
811 effectiveness of the device by introducing a new potential worst-case scenario for some
812 failure modes (e.g., mechanical failure of the plate, pain and irritation from prominence,
813 loss of screw stability).
814
- 815 • A change in sterilization method from “Established Category A” sterilization methods to
816 “Established Category B” or “Novel” sterilization methods – this type of change could
817 significantly affect the safety and effectiveness of the device by introducing a new or
818 increased risk of device contamination. See FDA’s guidance [“Submission and Review of
819 Sterility Information in Premarket Notification \(510\(k\)\) Submissions for Devices Labeled
820 as Sterile”](#)⁴⁰ for a discussion of sterilization methods.
821
- 822 • A change in material – a change in material type (except changes from a weaker
823 common metal to a stronger common metal, as discussed below), formulation, chemical
824 composition, or material processing could significantly affect the safety and effectiveness
825 of the device. The change may introduce new or increased biocompatibility concerns or a
826 change in the risks associated with device failure.
827
- 828 • A change in compatibility of system components – this change could significantly affect
829 the safety and effectiveness of the device by introducing a new worst-case scenario for a
830 failure mode or expand the indications for use of a cleared component.
831

832 FDA believes that the following modifications would generally not require a new 510(k):
833

- 834 • The addition of a bone plate, screw, or washer of identical design, material, and
835 processing to a legally marketed device, but of an intermediate size because this would
836 not generally introduce new or significantly modified risks or new worst-case failure
837 modes.
838
- 839 • Modification in the sterilization process from one category A method to another category
840 A method as defined in FDA’s guidance [“Submission and Review of Sterility](#)

³⁹ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device>.

⁴⁰ <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

841 [Information in Premarket Notification \(510\(k\)\) Submissions for Devices Labeled as](#)
842 [Sterile](#)” (e.g., steam sterilization, gamma irradiation sterilization), if the change in
843 sterilization method can be justified as having no significant deleterious effect on the
844 mechanical or material properties of the device throughout the duration of its shelf life.
845

- 846 • A change in material from a weaker common metal to a stronger common metal which
847 conforms to an FDA recognized standard(s) and has a history of safe use for the same
848 indications (e.g., change in device from commercially pure titanium to stainless steel per
849 ASTM F138 or a change from commercially pure titanium to titanium alloy per ASTM
850 F136) where no new or increased biocompatibility concerns have been introduced.
851
- 852 • A change in compatible screws to include larger diameters within the range of legally
853 marketed screws with the same intended use and anatomical location (e.g., a wrist plating
854 system cleared with 2.0mm screws is modified to also include a 2.7mm diameter screw of
855 the same type), if it can be justified that the larger diameter screw does not introduce
856 changes to the plate interface or other factors affecting worst case.

857
858
859
860
861
862
863
864
865

APPENDIX A

Example Table of Plate Test Methods and Data Summary

Table A.1 – Example summary of test summary information for single cycle bend testing of plates when performed per ASTM F382 *Standard Specification and Test Method for Metallic Bone Plates*. This represents an example of how test summary information may be organized.

	Definition	Worst-Case Subject Device	Predicate (510(k) submission number)
Parameter			
Description of plate	The bone plate thickness, width, length, and shape.		
Catalog or part number	The identifying series of letters and numbers which is designated to the worst-case construct used in testing and corresponds with the associated engineering drawings.		
Plate material (include ASTM or ISO specification if available)	The base material from which the components are manufactured.		
Center span length	The measured distance between the two loading rollers in the test setup.		
Loading span length	The distance between the support roller and the nearest loading roller.		
Loading roller diameter	The diameter of the construct used to load the subject plate.		
Control method (displacement or load)	The method which is used to determine failure of the plate has occurred.		
Displacement or load control rate utilized	The rate at which the applied load or displacement is recorded throughout the test simulation.		
Test termination criteria	The pre-determined displacement or load values which are used to determine the test termination.		
Sample size	The number of samples used.		
Results			

Contains Nonbinding Recommendations

Draft – Not for Implementation

	Definition	Worst-Case Subject Device	Predicate (510(k) submission number)
0.2% offset displacement (mean ± standard deviation)	Permanent deformation equal to 0.2% of the center loading span distance.		
Proof load (mean ± standard deviation)	The maximum applied load prior to plastic deformation of the plate.		
Bending structural stiffness (mean ± standard deviation)	A normalized calculation of the plate resistance to bending deformation which takes into account the test setup.		
Bending strength (mean ± standard deviation)	The stress required to produce a predetermined amount of plastic deformation of the plate, such as a 0.2% offset.		
Description of failure modes	The predetermined criteria for all methods of failure of the plate.		

866
867

868
869
870
871
872
873
874
875
876

APPENDIX B

Example Table of Screw Test Methods and Data Summary

Table B.1 – Example summary of test summary information for axial pullout strength testing of screws when performed per ASTM F543 *Standard Specification and Test Methods for Metallic Medical Bone Screws*. This represents an example of how test summary information may be organized.

	Definition	Worst-Case Subject Device	Predicate
Parameters			
Description of screw	The screw length, cannula size, major and minor thread diameter, threaded length, and pitch.		
Catalog or part number	The identifying series of letters and numbers which is designated to the worst-case construct used in testing and corresponds with the associated engineering drawings.		
Screw material (include ASTM or ISO specification if available)	The base material from which the components are manufactured.		
Pilot hole diameter (if applicable per the surgical technique)	The diameter of the hole which is pre-drilled into the test block into which the screw tip is inserted.		
Description of pilot hole preparation (e.g., is pilot hole pre-tapped or not)	Determination if the pilot hole will require a tap to be inserted into the pilot hole prior to the insertion of the screw.		
Test block material description	The test block Trade Name, material, and density.		
Displacement rate	The rate at which a tensile load is applied to the screw.		

Contains Nonbinding Recommendations

Draft – Not for Implementation

	Definition	Worst-Case Subject Device	Predicate
Final insertion depth	The final depth that the subject screw reaches into the test block after insertion.		
Grip span	The distance between the edge of the gripping structures holding the test block in place.		
Results			
Axial pullout strength (mean ± standard deviation)	The maximum load achieved before the screw releases from the test block.		
Description of the mode of failure	The observed method of failure for the screw upon release from the test block.		

877
878 **Table B.2 – Example summary of test summary information for insertion and removal**
879 **torque testing of screws when performed per ASTM F543: *Standard Specification and Test***
880 ***Methods for Metallic Medical Bone Screws*. This represents an example of how test**
881 **summary information may be organized.**
882

	Definition	Worst-Case Subject Device	Predicate
Parameters			
Description of screw	The screw length, cannula size, major and minor diameter, threaded length, and pitch		
Catalog or part number	The identifying series of letters and numbers which is designated to the worst-case construct used in testing and corresponds with the associated engineering drawings.		

Contains Nonbinding Recommendations

Draft – Not for Implementation

	Definition	Worst-Case Subject Device	Predicate
Screw material (include ASTM or ISO specification if available)	The base material from which the components are manufactured.		
Test block material description	The test block Trade Name, material, and density.		
Number of revolutions	The number of revolutions recorded when applying torsional force.		
Test speed	The rate of insertion/removal torque recorded throughout the test simulation.		
Description of pilot hole preparation (e.g., is pilot hole pre-tapped or not)	Determination if the pilot hole will require a tap to be inserted into the pilot hole prior to the insertion of the screw.		
Axial load	Determination of axial load to insert or remove the screw.		
Final insertion depth	The final depth that the subject screw reaches into the test block after insertion.		
Sample size	The number of samples used.		
Results			

Contains Nonbinding Recommendations

Draft – Not for Implementation

	Definition	Worst-Case Subject Device	Predicate
Insertion/removal torque (mean ± standard deviation)	The amount of torque required to insert/remove the screw from the test block during the initial four revolutions of the screw.		
Description of failure modes	The observed method of failure for the screw upon insertion or release from the test block.		

883
884
885
886
887
888
889

Table B.3 – Example summary of test summary information for torsional strength testing of screws when performed per ASTM F543: *Standard Specification and Test Methods for Metallic Medical Bone Screws*. This represents an example of how test summary information may be organized.

	Definition	Worst-Case Subject Device	Predicate
Parameters			
Description of screw	The screw length, cannula size, major and minor diameter, threaded length, and pitch		
Catalog or part number	The identifying series of letters and numbers which is designated to the worst-case construct used in testing and corresponds with the associated engineering drawings.		
Screw material (include ASTM or ISO specification if available)	The base material from which the components are manufactured.		
Grip Length	The length of the screw which is gripped in the test set-up		
Exposed Length	The length of the screw shaft which is exposed to loading		

Contains Nonbinding Recommendations

Draft – Not for Implementation

	Definition	Worst-Case Subject Device	Predicate
Control method (displacement or load)	The method which is used to determine failure of the screw has occurred.		
Displacement or load control rate utilized	The rate at which the applied load or displacement is recorded throughout the test simulation.		
Test termination criteria	The pre-determined displacement or load values which are used to determine the test termination.		
Sample size	The number of samples used.		
Results			
0.2% offset displacement (mean ± standard deviation)	Permanent displacement equal to 0.002 times the test gage section length for the specific test.		
Torsional yield strength (mean ± standard deviation)	The stress required to produce a predetermined amount of plastic deformation of the screw, such as a 0.2% offset.		
Description of failure modes	The predetermined criteria for all methods of failure of the plate.		

890